Philip Kantoff is Chairman and Chief Executive Officer of Convergent Therapeutics, a clinical-stage biotechnology company developing next-generation radiopharmaceutical therapies for prostate and other cancers. He co-founded the company in 2021 and has led its strategic direction, advancing its lead program, CONV01‑α, an alpha-emitting radioantibody targeting prostate-specific membrane antigen. Under his leadership, Convergent secured $90 million in Series A financing and received FDA clearance to begin clinical studies, moving its precision cancer therapies into active clinical development.
Before founding Convergent, Kantoff served as Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center and held senior leadership roles at Dana-Farber Cancer Institute and Harvard Medical School. His leadership combines scientific expertise and biotech innovation, positioning Convergent as an emerging company in targeted radiopharmaceutical therapies.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Most Influential CEOs in Oncology in 2025, and stay tuned for other special category nominations.
